# CBD Clinical Trials: Current State of Human Research

By Robin Roy Krigslund-Hansen | 12+ years in CBD industry
Last updated: January 21, 2026

---

## Quick Summary

CBD clinical trials have increased dramatically since 2018, with over 100 registered trials on ClinicalTrials.gov. The strongest evidence exists for epilepsy (leading to FDA-approved Epidiolex), with promising trials in anxiety, chronic pain, substance use disorders, and schizophrenia. Most trials are still Phase 1-2, meaning CBD research is progressing but far from complete for most conditions.

---

## Clinical Trial Phases Explained

### Phase 1: Safety Testing
- Small groups (20-100 healthy volunteers)
- Focus on safety and dosing
- Identifies side effects
- Determines how body processes CBD

### Phase 2: Initial Efficacy
- Larger groups (100-300 patients)
- Tests whether CBD works for intended use
- Continues safety monitoring
- Determines optimal dosing

### Phase 3: Confirmatory Efficacy
- Large groups (1,000-3,000 patients)
- Compares to existing treatments or placebo
- Required for regulatory approval
- Most expensive and rigorous phase

### Phase 4: Post-Market Surveillance
- After approval
- Monitors long-term effects
- Identifies rare side effects
- Optimizes use in real-world settings

---

## Completed and Published Trials

### Epilepsy (Strongest Evidence)
**Status:** Phase 3 completed, FDA approved

Key trials:
- **GWPCARE trials:** Led to Epidiolex approval
- **Dravet syndrome:** 43% reduction in convulsive seizures
- **Lennox-Gastaut syndrome:** 44% reduction in drop seizures

**Result:** First plant-derived cannabinoid medicine approved by FDA (2018)

### Anxiety
**Status:** Phase 2, promising results

Key findings:
- Multiple small trials show reduced anxiety scores
- Effective for social anxiety disorder in some studies
- Reduced anxiety in public speaking simulations
- Larger confirmatory trials needed

### Chronic Pain
**Status:** Phase 2, mixed results

Key findings:
- Some positive results for neuropathic pain
- Nabiximols (CBD+THC) approved in some countries
- CBD alone has weaker evidence than CBD+THC
- More large-scale trials needed

### Substance Use Disorders
**Status:** Phase 2, encouraging

Key findings:
- Reduced cue-induced craving in heroin users
- Possible benefit for cannabis use disorder
- Trials ongoing for opioid use disorder
- Mechanism may involve anxiety reduction

### Schizophrenia
**Status:** Phase 2, promising

Key findings:
- CBD may have antipsychotic properties
- Some trials show symptom improvement
- Different mechanism than traditional antipsychotics
- Needs larger confirmatory studies

---

## Ongoing Trials (2024-2026)

Major areas of active research:

| Condition | Number of Trials | Phase |
|-----------|------------------|-------|
| Epilepsy | 15+ | 2-4 |
| Anxiety disorders | 20+ | 1-3 |
| Chronic pain | 25+ | 1-3 |
| Cancer symptoms | 10+ | 1-2 |
| Autism | 5+ | 2 |
| PTSD | 8+ | 2 |
| Sleep disorders | 12+ | 1-2 |

---

## Notable Current Studies

### CBD for Pediatric Anxiety
- Phase 3 trial
- 150+ participants planned
- Comparing CBD to placebo
- Results expected 2026

### CBD for Opioid Use Disorder
- NIH-funded
- Phase 2 trial
- Examining CBD's effect on craving
- Part of larger addiction research initiative

### CBD for Fibromyalgia
- Multiple trials worldwide
- Phase 2
- Various formulations tested
- Mixed preliminary results

---

## Trial Limitations

### Common Issues
- **Small sample sizes:** Most trials have <200 participants
- **Short duration:** Often 4-12 weeks
- **Heterogeneous products:** Different CBD formulations complicate comparison
- **Placebo response:** High in many conditions studied
- **Funding challenges:** Limited pharmaceutical interest in non-patentable compound

### Quality Concerns
- Variable CBD product quality in trials
- Different administration methods
- Inconsistent dosing across studies
- Not all trials are registered or published

---

## Reading Trial Results

When you see trial results, consider:

1. **Sample size:** Larger is more reliable
2. **Comparison group:** Placebo-controlled is best
3. **Primary outcome:** Was the main measure met?
4. **Effect size:** How big was the difference?
5. **Statistical significance:** p-value < 0.05 typically required
6. **Clinical significance:** Big enough to matter in real life?

---

## How to Follow CBD Research

### Resources
- **ClinicalTrials.gov:** Search "cannabidiol" for all registered trials
- **PubMed:** Published trial results
- **Cochrane Reviews:** Systematic reviews when available
- **Our Research Database:** Curated CBD studies

### What to Look For
- Phase 3 trial completions
- Systematic reviews and meta-analyses
- Replication of promising Phase 2 results
- Real-world effectiveness studies

---

## My Take

CBD research has made remarkable progress since 2018, but we're still in relatively early stages for most conditions. The epilepsy success story shows what's possible with rigorous clinical development, but most CBD applications haven't reached that level of evidence.

I'm cautiously optimistic about ongoing trials in anxiety, pain, and addictionâ€”areas where preliminary results are encouraging. But I always remind people: being in a clinical trial is not the same as being proven effective. Many promising early-stage treatments ultimately don't pan out.

The best approach is informed patience: use what evidence we have, stay updated on new research, and maintain realistic expectations.

---

## Related Topics

- [Understanding CBD Research](/knowledge/understanding-cbd-research)
- [CBD and Epilepsy](/conditions/epilepsy)
- [CBD and Anxiety](/conditions/anxiety)
- [Future of Cannabinoid Research](/knowledge/future-cannabinoid-research)

---

*This article is for educational purposes only.*
